IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
- Results show UVIDEM was well-tolerated with signs of durabledisease control in advanced melanoma patients - IRVINE, Calif., June 05, 2007 /PRNewswire-FirstCall/ -- IDMPharma, Inc. today presented preliminary results from a Phase IIUVIDEM (IDD-3) melanoma vaccine clinical trial (DC-MEL-202). Theresults showed that UVIDEM was well tolerated with evidence ofefficacy and induction of immune...IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at 2007 ASCO Annual Meeting
IRVINE, Calif., May 30, 2007 /PRNewswire-FirstCall/ -- IDMPharma, Inc. today announced that data from a Phase II Uvidemmelanoma vaccine clinical trial and data from the Phase II EP-2101non-small cell lung cancer (NSCLC) vaccine clinical trial will bepresented at the 2007 American Society of Clinical Oncology (ASCO)43rd annual meeting in Chicago on June 1-5 2007. UVIDEM prese...